Corneal Persistent Epithelial Defect

Ophthalmology
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Glaukos
GlaukosALISO VIEJO, CA
1 program
1
Nexagon®Phase 2
Amber Therapeutics
1 program
1
Nexagon®Phase 21 trial
Active Trials
NCT04081103TerminatedEst. Feb 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Amber TherapeuticsNexagon®

Clinical Trials (1)

NCT04081103Amber TherapeuticsNexagon®

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

Start: Jun 2020Est. completion: Feb 2022
Phase 2Terminated

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
8h ago

Cleanroom and Laboratory Technician

SAB BIO
8h ago

APAC Regulatory Affairs Manager

Johnson & Johnson
Singapore, Singapore
Yesterday

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$117K - $201K/yr

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
Yesterday

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)